Great Lakes Advisors LLC Has $2.25 Million Stock Holdings in Enovis Corporation $ENOV

Great Lakes Advisors LLC boosted its holdings in shares of Enovis Corporation (NYSE:ENOV) by 9.8% in the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 58,826 shares of the company’s stock after purchasing an additional 5,242 shares during the quarter. Great Lakes Advisors LLC owned about 0.10% of Enovis worth $2,248,000 at the end of the most recent quarter.

Several other hedge funds also recently modified their holdings of the business. Vanguard Group Inc. increased its position in Enovis by 11.3% during the first quarter. Vanguard Group Inc. now owns 6,107,199 shares of the company’s stock worth $233,356,000 after acquiring an additional 621,069 shares during the period. Paradigm Capital Management Inc. NY grew its position in Enovis by 2,566.0% in the 4th quarter. Paradigm Capital Management Inc. NY now owns 533,200 shares of the company’s stock worth $23,397,000 after purchasing an additional 513,200 shares during the last quarter. Invenomic Capital Management LP increased its holdings in shares of Enovis by 199.6% during the 1st quarter. Invenomic Capital Management LP now owns 449,777 shares of the company’s stock worth $17,186,000 after purchasing an additional 299,658 shares during the period. DAVENPORT & Co LLC raised its position in shares of Enovis by 10.4% during the first quarter. DAVENPORT & Co LLC now owns 3,071,985 shares of the company’s stock valued at $116,489,000 after buying an additional 289,644 shares during the last quarter. Finally, Victory Capital Management Inc. lifted its stake in shares of Enovis by 734.5% in the first quarter. Victory Capital Management Inc. now owns 275,058 shares of the company’s stock valued at $10,510,000 after buying an additional 242,096 shares during the period. 98.45% of the stock is owned by institutional investors.

Enovis Stock Performance

Shares of NYSE:ENOV opened at $30.50 on Thursday. The company has a debt-to-equity ratio of 0.53, a current ratio of 2.25 and a quick ratio of 1.15. The business’s fifty day moving average price is $29.93 and its two-hundred day moving average price is $32.92. Enovis Corporation has a fifty-two week low of $25.47 and a fifty-two week high of $49.83. The stock has a market capitalization of $1.74 billion, a price-to-earnings ratio of -2.14 and a beta of 1.68.

Enovis (NYSE:ENOV) last issued its earnings results on Thursday, August 7th. The company reported $0.79 EPS for the quarter, beating the consensus estimate of $0.74 by $0.05. Enovis had a negative net margin of 37.80% and a positive return on equity of 6.78%. The company had revenue of $564.50 million for the quarter, compared to the consensus estimate of $555.80 million. During the same quarter in the previous year, the company earned $0.62 EPS. The firm’s revenue for the quarter was up 7.5% compared to the same quarter last year. Enovis has set its FY 2025 guidance at 3.050-3.200 EPS. As a group, analysts predict that Enovis Corporation will post 2.79 EPS for the current fiscal year.

Insider Transactions at Enovis

In other news, CFO Phillip Benjamin (Ben) Berry acquired 2,500 shares of the company’s stock in a transaction dated Wednesday, August 20th. The stock was bought at an average price of $29.71 per share, with a total value of $74,275.00. Following the completion of the acquisition, the chief financial officer owned 116,729 shares in the company, valued at approximately $3,468,018.59. This represents a 2.19% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Bradley J. Tandy bought 3,200 shares of Enovis stock in a transaction dated Friday, August 22nd. The stock was acquired at an average cost of $31.41 per share, for a total transaction of $100,512.00. Following the completion of the acquisition, the senior vice president directly owned 43,515 shares in the company, valued at $1,366,806.15. This represents a 7.94% increase in their ownership of the stock. The disclosure for this purchase can be found here. 2.70% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ENOV has been the topic of several research reports. UBS Group lowered their price target on Enovis from $65.00 to $57.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Evercore ISI lowered their price objective on Enovis from $48.00 to $46.00 and set an “outperform” rating on the stock in a research report on Tuesday, July 8th. Wells Fargo & Company cut their target price on Enovis from $48.00 to $41.00 and set an “overweight” rating for the company in a research note on Friday, August 8th. Canaccord Genuity Group decreased their price target on shares of Enovis from $70.00 to $58.00 and set a “buy” rating on the stock in a research note on Friday, August 8th. Finally, Needham & Company LLC dropped their price objective on shares of Enovis from $57.00 to $49.00 and set a “buy” rating for the company in a research note on Thursday, August 7th. Six analysts have rated the stock with a Buy rating, According to data from MarketBeat, the stock has a consensus rating of “Buy” and a consensus target price of $51.00.

Enovis Company Profile

Enovis Corporation operates as a medical technology company focus on developing clinically differentiated solutions worldwide. It also manufactures and distributes medical devices which are used for reconstructive surgery, rehabilitation, pain management, and physical therapy. The company operates through Prevention and Recovery, and Reconstructive segments.